Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Novel Niche Approach to Antibacterial Drug Development

This article was originally published in Start Up

Executive Summary

Researchers are finding new ways to disable bacteria, either by increasing their sensitivity to existing drugs or decreasing their virulence. Targeting bacterial functions that have a significant effect on growth in an infected host but are not thought of as "antimicrobial" may represent an important new drug development strategy. A group recently reported encouraging, if very early, results about the ability of an inhibitor of virulence factor biosynthesis to control tuberculosis infection.

You may also be interested in...



VLST Corp.

VLST is developing a platform around the identification and understanding of the function of virulence factors, a set of proteins in viruses that down regulate the host's immune response, thereby conferring a survival advantage. Understanding this evolutionary process can lead to the identification of a group of clinically relevant cellular targets, as the predicate for the development of therapeutics.

Antibacterial Drug Development

For some start-ups, keeping pace with Big Pharma's shifting business priorities means following a path of less resistance. New companies are being formed around Big Pharma assets that no longer fit their priorities and market needs; others are fueled by novel discovery approaches based on elucidating and harnessing the power of natural genetic mechanisms.

AvidBiotics Corp.

By harnessing the natural killing power of pyocins, a class of proteins produced in bacteria that enable the bacteria to kill related species, AvidBiotics expects to develop a new generation of engineered antibacterial proteins.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel